TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
* Histologic evidence of NASH based on a liver biopsy obtained within 6 months of randomization.~* Age 18 years or older

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pioglitazone
- 2 (Type: ACTIVE_COMPARATOR): Vitamin E
- 3 (Type: PLACEBO_COMPARATOR): Placebo Pioglitazone or Placebo Vitamin E

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Man who has sex with men~2. Age at least 18 years~3. Eligible for 3-drug NPEP according to Australian guidelines for the use of 3-drug NPEP following an actual or potential sexual exposure to HIV or receptive anal intercourse with an unknown source~4. Able to provide written, informed consent~5. Able to commit to the study visits~   Exclusion Criteria:~6. Non-sexual exposure~7. Exposure occurring during sex between a man and a woman~8. HIV infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary HIV infection~9. Use of any medication contraindicated with FTC-RPV-TDF~10. Serum hepatic transaminase (alanine aminotransferase \[ALT\] greater than 5 times the upper limit of the normal range~11. Serum estimated Glomerular Filtration Rate (eGFR) \<60mL/min/ BSAc~12. Current therapy for hepatitis B~13. Day 1 serological evidence of chronic/active hepatitis B~14. Previous NPEP containing FTC-RPV-TDF~15. A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eviplera (Type: OTHER): Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cesarean Section Via Enhanced Recovery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Any patient 18 years or older whom is scheduled for an elective cesarean section from one of the participating clinics: Prime Care, Maternal Fetal Medicine (MFM), Obstetrics Complications Clinic (OBCC).~Exclusion Criteria:~1. Age less than 18 years old;~2. urgent or emergent cesarean delivery;~3. diagnosis of preeclampsia;~4. coagulopathy that contraindicates neuraxial block placement;~5. abnormal placentation;~6. opioid abuse disorder;~7. type C diabetic or greater.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ERAS Implemented Group (Type: None): Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
- Pre-ERAS - Non-ERAS Implemented Group (Type: None): Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years with advanced or metastatic solid tumor not amenable to any clinical improvement by current standard treatments and suitable for a treatment with cisplatin~  * Life expectancy more than 3 months~ * ECOG Performance status 0-1~ * Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) may represent a risk for the patient~ * Adequate baseline bone marrow, hepatic and renal function, defined as follows:~ * Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L~ * Bilirubin \< 1.5 x ULN~ * AST and/or ALT \< 2.5 x ULN in absence of liver metastasis~ * AST and/or ALT \< 5 x ULN in presence of liver metastasis~ * Serum creatinine \< 1.5 x ULN~ * Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min~ * Patients may have had prior therapy providing the following conditions are met:~* Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days~* Corticosteroid therapy wash out period of 14 days~* Surgery: wash-out period of 14 days~* Patients must give written informed consent to participate in the study~Exclusion Criteria:~* Previous signs of severe toxicity platinum related~* Patients must not receive any other investigational agents while on study~* New York Heart Association class III or IV cardiac disease~* Unstable angina~* Patients with myocardial infarction within the last six (6) months~* Patient with significant peripheral vascular disease~* Clinical signs of CNS involvement~* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol~* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol~* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (HBV):~* HBsAg+ for at least 6 months prior to initiation of treatment.~* HBeAg+~* HBV titer \> 20000 copies/ml at start of treatment~* Treatment naïve~* HIV / hepatitis delta / HCV negative~* Compensated liver disease~* Ishak score ≤ 2~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC (REP 2055) and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Inclusion Criteria (HCV):~* HCV positive for at least 6 months prior to initiation of treatment~* Genotype 3~* HCV titer \>3log IU/ml at start of treatment~* Treatment naïve~* HIV / hepatitis delta / HBV negative~* Compensated liver disease~* Chronic alanine aminotransferase or aspartate aminotransferase elevation for 6 months prior to treatment~* Ishak score ≤ 2 (patients should only have mild fibrosis)~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC (REP 2055) and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Exclusion Criteria (HBV + HCV):~* Evidence of cardiovascular disease~* Autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* Anti-nuclear antibody): positive~* Anti-HIV 1: positive~* Evidence of liver cirrhosis~* A history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 75,000, polymorphonuclear cell count \< 1,500 or hematocrit \< 33%~* Alfa feto protein \> 100 ng/ml or the presence of a hepatic mass suggestive of hepatocellular carcinoma.~* Bilirubin \> 2.5 mg/dl~* Creatinine \> 1.5 mg/dl~* Platelets count \< 75,000 / cmm~* Serum albumin \< 35 mg/ml~* Poorly controlled diabetes mellitus~* Another serious medical disorder~* A serious psychiatric disorder~* Uncontrolled hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Positive pregnancy test~* Breastfeeding~* Inability or unwillingness to undergo a liver biopsy.~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making weekly IV infusion too difficult

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2055 (Type: EXPERIMENTAL): Treatment with REP 2055

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inborn infants at term gestation (38-42 weeks)~* Apgar score ≤ 3 at 5 minutes and/or delayed first breath beyond five minutes after birth~* Profound metabolic or mixed acidosis with serum bicarbonate \<12 mMol/L in initial arterial blood gas~* Evidence of encephalopathy such as stupor, coma, seizures, or hypotonia in the immediate neonatal period~Exclusion Criteria:~* Twin gestation~* Maternal diabetes~* Congenital malformations of the central nervous system~* Chromosomal abnormalities~* Chorioamnionitis and congenital infections~* Intrauterine growth restriction

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- EPO HIE Group (Type: EXPERIMENTAL): Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
- Control HIE (Type: NO_INTERVENTION): Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
- Healthy Controls (Type: OTHER): Healthy newborn without hypoxic ischemic encephalopathy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Fibrin Pad Liver Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects \> 18 years of age, requiring elective or urgent, open hepatic surgery~* Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon~* Subjects must be willing to participate in the study, and provide written informed consent~Exclusion Criteria:~* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure~* TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the FP to blood flow and pressure during healing and absorption of the product~* TBS with major arterial bleeding requiring suture or mechanical ligation~* Subjects admitted for trauma surgery~* Subject is a transplant patient for fulminant hepatic failure~* Subject with TBS within an actively infected field~* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine~* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products~* Subjects who are known, current alcohol and / or drug abusers~* Subjects who have participated in another investigational drug or device research study within 30 days of surgery~* Female subjects who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibrin Pad (Type: EXPERIMENTAL): Biologic
- Standard of Care (Type: OTHER): Procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nicotinic Receptor Augmentation of SSRI Antidepressants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Major depression, recurrent outpatients, ages 18-65, smoker or non-smoker, on SSRI monotherapy, depression scores on HDRS-17 item scale or = 12.~Exclusion Criteria:~* suicidal or homicidal ideation, need for inpatient or partial hospital care, systolic blood pressure \<100 mm Hg, history of hypersensitivity to mecamylamine or its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or above, or above legal age to give informed consent specific to state and national law~2. Willing and capable of providing informed consent~3. Planned to be implanted or replaced with a VISIONIST Ingenio 2 CRT-P device~4. Planned to be implanted with a 3-lead CRT-P system~5. Planned to be connected to the remote data collection through the Latitude® system~6. Able to do a 6 minute walk test~7. Maximum sensor rate of age predicted maximal heart rate (APMHR) 80% should be clinically acceptable~8. Willing and capable of participating in all visits associated with this study at an approved clinical study center and at the intervals defined-~Exclusion Criteria:~1. Documented life expectancy of less than 12 months~2. Currently on the active heart transplant list~3. Enrolled in any other concurrent study without prior written approval from Boston Scientific, with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:~   * Schedule of procedures for the Rally CRT-P Study (i.e., should not cause additional or missed visits)~  * Rally CRT-P Study outcomes (i.e., involve medications that could affect the heart rate of the subject)~  * Conduct of the Rally CRT-P Study per Good Clinical Practice (GCP)/ International Standard Organization (ISO) 14155:2011/ local regulations as applicable~4. In chronic atrial fibrillation~5. APMHR needs to be programmed \< 80%.~6. Not planned to receive a functional atrial lead~7. Per the implanting physician's discretion, subject is not a suitable candidate to receive the study device as determined during the implant procedure~8. Women of childbearing potential who are or might be pregnant at the time of study enrollment~9. Unwilling or unable to participate in all scheduled study follow up visits at an approved study center~10. Does not anticipate being a resident of the area for the scheduled duration of the trial. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT-P indicated patients (Type: None): Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Major inclusion criteria~Diagnosis/Trial Population~* Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):~  * history of diagnosis of CLL or SLL that meets IWCLL diagnostic criteria~ * histologically confirmed diagnosis of SLL by lymph node biopsy~ * indication for treatment as defined by the IWCLL guidelines~* Patients must have both of the following:~  * relapsed or refractory disease while receiving a BTKi therapy or intolerance of such therapy~ * single-agent or combination therapy with a BTKi for at least one month must be the patient's most recent prior anticancer therapy~* ECOG performance status of 0 to 2~* Patients with a past medical history of autologous or allogeneic stem cell transplantation must exhibit full hematological recovery~Laboratory Values~• Patients must meet adequate bone marrow function and adequate hepatic and renal function~Other Inclusion Criteria~• Females of childbearing potential must use a highly effective method of contraception~Major exclusion criteria~Diagnosis~• Patients who have:~* non-Hodgkin's lymphomas other than CLL/SLL~* transformed CLL/SLL or Richter's syndrome~* active and uncontrolled autoimmune cytopenia~Previous and Current Treatment~* Patients who have received treatment with a BTK inhibitor within 5 days prior to Day 1 dosing~* Patients who have, within 14 days prior to D1 dosing:~  * not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy~ * systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day with the exception of patients with signs of rapidly progressing disease~ * received live vaccines with the exception of vaccination against influenza with inactivated virus or for pneumococcal diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): tafasitamab (MOR208) in combination with idelalisib
- Cohort B (Type: EXPERIMENTAL): tafasitamab (MOR208) in combination with venetoclax

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (either newly diagnosed, or relapsing) with peritoneal carcinomatosis from histo-pathologically proven colorectal carcinoma who are candidate for open surgery,~* Informed consent form signed.~Exclusion Criteria:~* Age less than18 years old.~* Inability to give informed consent.~* History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.~* Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomy of the thyroid gland.~* Documented coronary disease.~* Advanced renal impairment (creatinine \> 1,5mg/dl).~* During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).~* Pregnancy, breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indocyanine Green (Type: EXPERIMENTAL): Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patient has GAD as the primary diagnosis according to DSM-IV-TR criteria (classification code 300.02).~* The patient has a HAM-A total score \>=20 at screening and baseline visits~* The patient has a HAM-A score \>=2 on both Item 1 (anxious mood) and Item 2 (tension) at screening and baseline visits~* The patient has a MADRS total score \<=16 at screening and baseline visits~Exclusion Criteria:~* Any current psychiatric disorder other than GAD as defined in the DSM-IV-TR (assessed with the MINI)~* Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR~* Women of childbearing potential not using effective contraception~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lu AA21004 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete